Comparison of lesion level and ischemic modified albumin in peripheral artery disease

Abstract

Aim: Research is ongoing to discover biomarkers that can be used to monitor disease progression and predict prognosis in peripheral artery disease (PAD). Ischemia-modified albumin (IMA) is known to predict the risk for PAD. The aim of this study was to investigate whether serum IMA levels were associated with PAD lesions and ankle-brachial index (ABI) values, and to determine the accuracy of IMA levels in predicting PAD prognosis. Material and Method: Seventy-three patients with PAD who applied to our hospital between July and September 2018 were included in the study. The lesion levels of patients with an ankle-brachial index (ABI) value lower than or equal to 0.9 were determined by computed tomography angiography (CTA). Patients were grouped according to their lesion levels and Fontaine classification. Serum IMA concentrations were measured and compared with regard to lesion levels and ABI values. Results: Sixty-five of the patients (89%) were male. The mean age of the patients was 62.2 ± 8.8 (43–77) years. The mean serum IMA level was 25.9 ± 26.7 (10–218) ng/ml. Serum IMA levels were found to be lower in patients with bilateral iliac artery lesions (p = 0.040). There was no statistically significant relationship between other parameters and serum IMA levels (p >0.05 for all). Conclusion: There is a need for biomarkers that can predict lesion level and prognosis in patients with PAD. Although no statistically significant relationship was found between lesion level and serum IMA concentrations in this study, further studies involving a higher number of patients may provide more informative data on this subject.

Keywords

• Ischemia-modified albumin
• peripheral artery disease
• ankle-brachial index

References

1. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic).... Circulation 2006; 113: e463-e654.
2. Karabay Ö, Karaçelik M, Yılık L, et al. Ischemic peripheral arterial disease: A screening survey. Turkish journal of thoracıc and cardıovascular surgery 2012; 20: 450-7.
3. Küçükşen S, Toker A, Küçük A, et al. Evaluation of ischemia modified albumin levels and carotid intima media thickness in patients with systemic lupus eythematosus. Eur J Basic Med Sci, 2014; 4: 77-82.
4. Ma SG, Wei CL, Hong B, Yu WN. Ischemia-modified albumin in type 2 diabetic patients with and without peripheral arterial disease. Clinics 2011; 66: 1677-80.
5. Sbarouni E, Georgiadou P, Voudris V. Ischemia modified albumin changes - review and clinical implications. Clin Chem Lab Med 2011; 49: 177-84
6. Piwowar A, Knapik-Kordecka M, Warwas M. Ischemia-modified albumin level in type 2 diabetes mellitus-Preliminary report. Dis Markers 2008; 24: 311-7.
7. Bar‐Or D, Curtis G, Rao N, Bampos N, Lau E. Characterization of the Co2+ and Ni2+ binding amino‐acid residues of the N‐terminus of human albumin. Eur J Biochem 2001; 268: 42-8.
8. Ozkan U, Oguzkurt L, Tercan F. Atherosclerotic risk factors and segmental distribution in symptomatic peripheral artery disease. J Vasc Interv Radiol 2009; 20: 437

9. Diehm C, Kareem S, Lawall H. Epidemiology of peripheral arterial disease. Vasa. 2004; 33: 183-9
10. Cooke JP, Wilson AM. Biomarkers of peripheral arterial disease. J Am Coll Cardiol 2010; 55: 2017–23.
11. Bragadeesh T, Sari I, Pascotto M, Micari A, Kaul S, Lindner JR. Detection of peripheral vascular stenosis by assessing skeletal muscle flow reserve. J Am Coll Cardiol 2005; 45: 780–5.
12. Zimmerman BJ, Granger DN. Mechanisms of reperfusion injury. Am J Med Sci 1994; 307: 284-92.
13. Roy D, Quiles J, Sharma R, et al. Ischemia-modified albumin concentrations in patients with peripheral vascular disease and exercise-induced skeletal muscle ischemia. Clin Chem 2004; 50: 1656-60.